{"title":"Elevated levels of peripheral and central nervous system immune markers reflect innate immune dysregulation in autism spectrum disorder","authors":"","doi":"10.1016/j.psychres.2024.116245","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Evidence suggests dysregulated immune functions in the pathophysiology of Autism spectrum disorder (ASD), although specific immune mechanisms are yet to be identified.</div></div><div><h3>Methods</h3><div>We assessed circulating levels of 25 immune/neuroinflammatory markers in a large ASD sample (<em>n</em> = 151) and matched controls (<em>n</em> = 72) using linear models. In addition, we performed global brain transcriptomics analyses of relevant immune-related genes. We also assessed the expression and function of factors and pathway elements of the inflammasome system in peripheral blood mononuclear cells (PBMC) isolated from ASD and controls using <em>in vitro</em> methods.</div></div><div><h3>Results</h3><div>We found higher circulating levels of IL-18 and adhesion factors (ICAM-1, MADCAM1) in individuals with ASD relative to controls. Consistent with this, brain levels of <em>ICAM1</em> mRNA were also higher in ASD compared to controls. Furthermore, we found higher expression/activity of Caspase-1 and the inflammasome sensor NLRP3 in PBMCs in ASD, both at baseline and following inflammatory challenge. This corresponded with higher levels of secreted IL-18, IL-1β, and IL-8, as well as increased expression of adhesion factors following inflammasome activation in ASD PBMC cultures. Inhibition of the NLRP3-inflammasome rescued the observed immune phenotype in ASD <em>in vitro</em>.</div></div><div><h3>Conclusion</h3><div>Our results suggest a role for inflammasome dysregulation in ASD pathophysiology.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatry Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165178124005304","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Evidence suggests dysregulated immune functions in the pathophysiology of Autism spectrum disorder (ASD), although specific immune mechanisms are yet to be identified.
Methods
We assessed circulating levels of 25 immune/neuroinflammatory markers in a large ASD sample (n = 151) and matched controls (n = 72) using linear models. In addition, we performed global brain transcriptomics analyses of relevant immune-related genes. We also assessed the expression and function of factors and pathway elements of the inflammasome system in peripheral blood mononuclear cells (PBMC) isolated from ASD and controls using in vitro methods.
Results
We found higher circulating levels of IL-18 and adhesion factors (ICAM-1, MADCAM1) in individuals with ASD relative to controls. Consistent with this, brain levels of ICAM1 mRNA were also higher in ASD compared to controls. Furthermore, we found higher expression/activity of Caspase-1 and the inflammasome sensor NLRP3 in PBMCs in ASD, both at baseline and following inflammatory challenge. This corresponded with higher levels of secreted IL-18, IL-1β, and IL-8, as well as increased expression of adhesion factors following inflammasome activation in ASD PBMC cultures. Inhibition of the NLRP3-inflammasome rescued the observed immune phenotype in ASD in vitro.
Conclusion
Our results suggest a role for inflammasome dysregulation in ASD pathophysiology.
期刊介绍:
Psychiatry Research offers swift publication of comprehensive research reports and reviews within the field of psychiatry.
The scope of the journal encompasses:
Biochemical, physiological, neuroanatomic, genetic, neurocognitive, and psychosocial determinants of psychiatric disorders.
Diagnostic assessments of psychiatric disorders.
Evaluations that pursue hypotheses about the cause or causes of psychiatric diseases.
Evaluations of pharmacologic and non-pharmacologic psychiatric treatments.
Basic neuroscience studies related to animal or neurochemical models for psychiatric disorders.
Methodological advances, such as instrumentation, clinical scales, and assays directly applicable to psychiatric research.